Evidence map›Paper›PMID 38077015›Full record

ArticleResearch square2023

Host immune responses associated with SARS-CoV-2 Omicron infection result in protection or pathology during reinfection depending on mouse genetic background.

Gagandeep Singh, Prajakta Warang, Juan García-Bernalt Diego, Lauren Chang, Yonina Bykov, Sarabjot Singh, Lars Pache, Sara Cuadrado-Castano, Brett Webb, Adolfo Garcia-Sastre and 1 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Gagandeep SinghIcahn School of Medicine at Mount Sinai.ORCID 0000-0003-3260-2631
Prajakta WarangIcahn School of Medicine at Mount Sinai.
Juan García-Bernalt DiegoIcahn School of Medicine at Mount Sinai.
Lauren ChangIcahn School of Medicine at Mount Sinai.ORCID 0000-0002-3287-3987
Yonina BykovIcahn School of Medicine at Mount Sinai.
Sarabjot SinghRT-PCR COVID-19 Laboratory, Civil Hospital, Moga, Punjab, India.
Lars PacheSanford Burnham Prebys Medical Discovery Institute.ORCID 0000-0002-4193-1042
Sara Cuadrado-CastanoIcahn School of Medicine at Mount Sinai.ORCID 0000-0002-9400-746X
Brett WebbDepartment of Veterinary Sciences, University of Wyoming.
Adolfo Garcia-SastreIcahn School of Medicine at Mount Sinai.ORCID 0000-0002-6551-1827
Michael SchotsaertIcahn School of Medicine at Mount Sinai.ORCID 0000-0003-3156-3132
Icahn School of Medicine at Mount Sinai · USSanford Burnham Prebys Medical Discovery Institute · USUniversity of Wyoming · US

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
Supplement: Adjuvant Screening for an inactivated SFTSV Vaccine75N93019C00046 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ADOLFO, GARCIA-SASTRE · 2019 to 2023
$9.1M
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacyR01AI160706 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHOTSAERT, MICHAEL, WONG, PAMELA TINMOI · 2022 to 2025
$2.9M
Experimental and natural SARS-CoV-2 infection of the human pancreasR01DK130425 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOMANN, DIRK, SCHOTSAERT, MICHAEL · 2021 to 2023
$1.3M
NIAID NIH HHS 75N93019C00046NIAID NIH HHS 75N93021C00014NIAID NIH HHS R01 AI160706NIDDK NIH HHS R01 DK130425
6 · The paper itself

Abstract

Rapid emergence of antigenic distinct SARS-CoV-2 variants implies a greater risk of reinfection as viruses can escape neutralizing antibodies induced by vaccination or previous viral exposure. Disease severity during COVID-19 depends on many variables such as age-related comorbidities, host immune status and genetic variation. The host immune response during infection with SARS-CoV-2 may contribute to disease severity, which can range from asymptomatic to severe with fatal outcome. Furthermore, the extent of host immune response activation may rely on underlying genetic predisposition for disease or protection. To address these questions, we performed immune profiling studies in mice with different genetic backgrounds - transgenic K18-hACE2 and wild-type 129S1 mice - subjected to reinfection with the severe disease-causing SARS-CoV-2 B.1.351 variant, 30 days after experimental milder BA.1 infection. BA.1 preinfection conferred protection against B.1.351-induced morbidity in K18-hACE2 mice but aggravated disease in 129S1 mice. We found that he cytokine/chemokine profile in B.1.351 re-infected 129S1mice is similar to that during severe SARS-CoV-2 infection in humans and is characterized by a much higher level of IL-10, IL-1β, IL-18 and IFN-γ, whereas in B.1.351 re-infected K18-hACE2 mice, the cytokine profile echoes the signature of naïve mice undergoing viral infection for the first time. Interestingly, the enhanced pathology observed in 129S1 mice upon reinfection cannot be attributed to a less efficient induction of adaptive immune responses to the initial BA.1 infection, as both K18-hACE2 and 129S1 mice exhibited similar B and T cell responses at 30 DPI against BA.1, with similar anti-BA.1 or B.1.351 spike-specific ELISA binding titers, levels of germinal center B-cells, and SARS-CoV-2-Spike specific tissue-resident T-cells. Long-term effects of BA.1 infection are associated with differential transcriptional changes in bronchoalveolar lavage-derived CD11c + immune cells from K18-hACE2 and 129S1, with K18-hACE2 CD11c + cells showing a strong antiviral defense gene expression profile whereas 129S1 CD11c + cells showed a more pro-inflammatory response. In conclusion, initial infection with BA.1 induces cross-reactive adaptive immune responses in both K18-hACE2 and 129S1 mice, however the different disease outcome of reinfection seems to be driven by differential responses of CD11c + cells in the alveolar space.

Identifiers

PMID38077015
PMCPMC10705603
OpenAlexW4389131837

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.